Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01425138
Previous Study | Return to List | Next Study

Systematic Review And Meta-Analysis Of Psoriasis Treatments.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01425138
Recruitment Status : Completed
First Posted : August 29, 2011
Last Update Posted : December 3, 2018
Sponsor:
Collaborator:
University of Connecticut School of Pharmacy and Hartford Hospital
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date August 26, 2011
First Posted Date August 29, 2011
Last Update Posted Date December 3, 2018
Study Start Date June 2009
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: August 26, 2011)
  • Physician Global Assessment (PGA)
  • Dermatology Life Quality Index (DLQI)
  • Short-Form 36 (SF-36)
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: September 20, 2011)
No secondary outcomes [ Time Frame: No secondary outcomes ]
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Systematic Review And Meta-Analysis Of Psoriasis Treatments.
Official Title Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis
Brief Summary This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.
Detailed Description This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Moderate-to-severe plaque psoriasis published trials.
Condition Psoriasis
Intervention Not Provided
Study Groups/Cohorts Psoriasis
Published data on moderate-to-severe plaque psoriasis.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 29, 2018)
1
Original Estimated Enrollment
 (submitted: August 26, 2011)
0
Actual Study Completion Date June 2011
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
  • Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

  • Trials that did not report the Physician's Global Assessment (PGA),
  • Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01425138
Other Study ID Numbers A3921142
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators University of Connecticut School of Pharmacy and Hartford Hospital
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date November 2018